EP Vantage
EP Vantage
Stop FollowingEP Vantage
View as an RSS Feed
View EP Vantage's Articles BY TICKER:
ABII,
ABT,
AFFY,
ALIM,
ALIOF.PK,
ALNY,
ALTH,
ALXN,
AMGN,
ARIA,
ARQL,
ASTM,
AZN,
BAX,
BCRX,
BMTI,
BMY,
BSNRF.PK,
BSX,
CADX,
CBST,
CELG,
CEPH,
CHTP,
CORT,
COV,
CYPB,
CYTK,
DDSS,
DEPO,
DMYDF.PK,
DNDN,
ECYT,
ESALY.PK,
EW,
FOLD,
FRX,
GE,
GILD,
GSK,
GTXI,
HALO,
HEB,
IMGN,
INHX,
ISPH,
ISTA,
ITMN,
JAZZ,
JNJ,
KG,
LLY,
LMNX,
MDCO,
MDT,
MDVN,
MEDX,
MKGAF.PK,
MNKD,
MYGN,
NAVB,
NEUSF.PK,
NVS,
NYMX,
OMER,
ONXX,
OPOSF.PK,
PARD.PK,
PCYC,
PFE,
PPHM,
RHHBY.OB,
RIGL,
SCR,
SNN,
SNY,
STJ,
SVNT,
SXMDF.PK,
TEVA,
THRX,
TMO,
UCBJY.PK,
UTHR,
VPHM,
VRX,
VVUS,
WILLF.PK,
WMGI,
YMI
- Bristol-Myers Squibb Boosted by Good News on Yervoy
- Gilead Takes Small but Important Step With HIV Therapy
- Aflibercept Setback in Cancer More Worrying for Sanofi Than Regeneron
- Pfizer Needs Rheumatoid Arthritis Drug to Keep Performing
- Niche Opportunity May Be Slipping From Protalix's Grasp
- Gilead Makes Smart Moves in a New Direction
- Sanofi / Genzyme Deal Throws Spotlight on CVRs
- Sanofi/Genzyme: Smart Move That Will Mean Accelerated Growth
- Cadence Pharmaceuticals Needs Fast-Paced Ofirmev Launch to Build Confidence
- Roche's Avastin Scores Again in Ovarian Cancer but Doubts Remain
- Alimera Clears Some of the Muddle on Eye Implant Data but Nervousness Still Warranted
- Novo Confirms Potential in New Insulin but Challenges Remain
- Depomed Gains Gabapentin Approval as Abbott Spat Looms
- Sanofi-Aventis' Most Promising Clinical Candidate Takes a Nasty Fall
- Eisai's Rollercoaster: Sepsis Drug Failure Overshadows Eventful Few Days
- Eli Lilly's Alzheimer's Diagnostic Steps Closer to Market
- Another Major Setback for MannKind's Inhaled Insulin
- Psoriasis Drug Setback Highlights Abbott Pipeline Weaknesses
- Hopes Fading for Merck's Anticoagulant
- Lilly-Boehringer Diabetes Deal Seeks Safety in Numbers
- Inspire Pharmaceuticals: Looking for Inspiration Following Denufosol Failure
- Alimera Gets Unwelcome Christmas Message From FDA
- AstraZeneca Scraps Respiratory Drug: No Surprise, But Still Unwelcome News
- AstraZeneca's Blood-Thinner Hits Another FDA Roadblock as Company Faces Patent Cliff
- Cytokinetics ALS Data Raises Hopes, May Be Onto Something
- Cephalon Stem Cell Deal Catches Analysts Off-Guard
- Valeant, GSK Prepare for Approval of Anti-Epileptic Drug Despite Latest Delay
- Silver Lining for Affymax in Likely Drug Submission Next Year
- Actelion Takeover: Constant Speculation, Doubts Linger
- Investors May Yet Give Aastrom a Second Chance
- Amgen: FDA OK for Osteoporosis Therapy Is Welcome News
- Roche Unveils Welcome Show of Earnings Strength